Researchers at Ohio State University have made a groundbreaking advancement in the field of cancer treatment with a new gene therapy that utilizes light to target the mitochondria—the powerhouses of cancer cells.
The goal of this innovative approach is to trigger extensive cell death.
In experiments conducted on mice, scientists utilized nanoparticles to deliver a gene therapy designed to disrupt mitochondrial function.
The outcome was promising, showing substantial reductions in tumors associated with glioblastoma and aggressive breast cancer.
Introducing mLumiOpto
Named mLumiOpto, this cutting-edge technology generates light-activated electrical currents within cancer cells.
This process ultimately leads to mitochondrial collapse and initiates programmed cell death, also known as apoptosis.
Lufang Zhou, one of the lead researchers, explains that this therapy effectively damages the mitochondrial membrane, which stops energy production and aggravates DNA damage.
Unlike traditional treatments that target specific biological pathways, mLumiOpto zeroes in directly on the mitochondria.
Targeted Delivery Mechanism
To facilitate this targeted delivery, the research team employed a specially designed variant of the adeno-associated virus.
This form of the virus has been modified to selectively infect cancer cells.
The researchers achieved this remarkable specificity by integrating genetic sequences that encode a light-sensitive protein along with a bioluminescent enzyme, allowing them to precisely direct their therapy to the intended location.
Promising Results
During their studies, the researchers noted a significant reduction in tumor size and an increase in overall survival rates among treated mice.
Remarkably, the therapy managed to focus its effects on malignant cells, sparing healthy tissues from damage.
Furthermore, the treatment appeared to stimulate an immune response against the cancer cells within the tumor’s microenvironment, complementing the primary effects of the therapy.
This innovative research highlights the potential of mLumiOpto in cancer treatment, prompting the team to file a provisional patent for their technology.
The exciting findings from this study were shared in the well-respected journal, Cancer Research.
Overall, this work not only opens new avenues in oncology but also embodies a fresh perspective on how gene therapy can be effectively utilized to combat cancer.
Source: ScienceDaily